



STW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/531,660

Confirmation No.: 3876

Applicant: Luis Molina

Filed: April 15, 2005

TC/AU.: 1654

Examiner: Marcela M. Cordero Garcia

Docket No.: 11299.105005 L1 3000 MMI/2

Customer No.: 20786

Title: Methods of Treating Dry Eye Disease with Lantibiotics

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the accompanying Form PTO/SB/08A, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A list of each cited reference is enclosed, except for the U.S. Patents and U.S. Patent Applications. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe that any fees are due because this paper is being submitted before the mailing of a first Office Action on the merits, as under 37 C.F.R. § 1.97(b)(3). However, should the Commissioner determine that fees are due, he is hereby authorized to charge such fees and to credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,



Stephanie D. Adams, Ph.D.


Reg. No. 47,378

Dated: February 17, 2006

King & Spalding LLP  
191 Peachtree Street, 45<sup>th</sup> Floor  
Atlanta, GA 30303-1763  
Office: (404) 572-4600/ Fax: (404) 572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on February 17, 2006.



Sharon Sullivan

Sharon Sullivan

FEB 21 2006

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

5

***Complete if Known***

Application Number	10/531,660
Filing Date	April 15, 2005
First Named Inventor	Luis Molina
Group Art Unit	1654
Examiner Name	Marcela M. Cordero Garcia
Attorney Docket Number	11299.105005 L1 3000 MMI/2

4005632\_1.DOC

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	4,209,505	A	Mikhail	06-24-1980	
	AB	5,137,728	A	Bawa	08-11-1992	
	AC	5,512,269	A	Molina y Vedia <i>et al.</i>	04-30-1996	
	AD	5,641,781	A	Cuberes-Alsistent, <i>et al.</i>	06-24-1997	
	AE	5,651,957	A	Molina y Vedia <i>et al.</i>	07-29-1997	
	AF	5,683,675	A	Molina y Vedia <i>et al.</i>	11-04-1997	
	AG	5,716,931	A	Molina y Vedia <i>et al.</i>	02-10-1998	
	AH	5,849,706	A	Molina y Vedia <i>et al.</i>	12-15-1998	
	AI	5,900,407	A	Yerxa <i>et al.</i>	05-04-1999	
	AJ	5,968,913	A	LaCroix, <i>et al.</i>	10-19-1999	
	AK	5,972,988	A	Macias	10-26-1999	
	AL	5,981,473	A	Barefoot <i>et al.</i>	11-09-1999	
	AM	6,027,715	A	Poznelo	02-22-2000	
	AN	6,043,219	A	Iandolo <i>et al.</i>	03-28-2000	
	AO	6,136,794	A	Cook <i>et al.</i>	10-24-2000	
	AP	6,159,952	A	Shaffer <i>et al.</i>	12-12-2000	
	AQ	6,200,551	B1	Morgan	03-13-2001	
	AR	6,221,357	B1	Bok <i>et al.</i>	04-24-2001	
	AS	6,268,380	B1	Tjoeng <i>et al.</i>	07-31-2001	
	AT	6,277,855	A	Yerxa	08-21-2001	
	AU	6,291,469	B1	Fisher <i>et al.</i>	09-18-2001	
	AV	6,315,996	B1	O'Callaghan	11-13-2001	
	AW	6,319,908	B1	Yerxa <i>et al.</i>	11-20-2001	
	AX	6,331,529	B1	Yerxa <i>et al.</i>	12-18-2001	
	AY	6,348,589	B1	Pendergast <i>et al.</i>	02-19-2002	
	AZ	6,387,886	B1	Montgomery <i>et al.</i>	05-14-2002	
	AAA	6,420,347	B1	Jacobus <i>et al.</i>	07-16-2002	
	AAB	6,423,694	B1	Drutz <i>et al.</i>	07-23-2002	
	AAC	6,423,721	B1	Harris <i>et al.</i>	07-23-2002	
	AAD	6,444,695	B1	Mahajan <i>et al.</i>	09-03-2002	
	AAE	6,448,276	B1	Yerxa	09-10-2002	
	AAF	6,451,288	B1	Boucher <i>et al.</i>	09-17-2002	
	AAG	6,462,028	B2	Pendergast <i>et al.</i>	10-08-2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

5

**Complete if Known**

Application Number	10/531,660
Filing Date	April 15, 2005
First Named Inventor	Luis Molina
Group Art Unit	1654
Examiner Name	Marcela M. Cordero Garcia
Attorney Docket Number	11299.105005 L1 3000 MMI/2

4005632\_1.DOC

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
BA	6,489,335	B2		Peyman	12-03-2002	
BB	6,548,658	B2		Yerxa	04-15-2003	
BC	6,565,861	B1		Tiffany et al.	05-20-2003	
BD	6,569,903	B2		Honma et al.	05-27-2003	
BE	6,596,725	B2		Peterson et al.	07-22-2003	
BF	6,656,920	B2		Fox et al.	12-02-2003	
BG	6,673,779	B2		Jacobus et al.	01-06-2004	
BH	6,693,109	B2		Fisher et al.	02-17-2004	
BI	2004-0033955	A1		Catania et al.	02-19-2004	
BJ	6,713,458	B1		Yerxa et al.	03-30-2004	
BK	6,716,813	B2		Lim et al.	04-06-2004	
BL	2005-0506282	A1		Molina	11-10-2005	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
BM	JP	2002-053492	A2		Santen Pharm.; Inspire Pharm.	02-19-2002		
BN	WO	94/28726	A2		Wellcome Found.; U. No. Carol.	12-22-1994		
BO	WO	98/34593	A1		Inspire Pharmaceuticals	08-13-1998		
BP	WO	99/09998	A1		Inspire Pharmaceuticals	03-04-1999		
BQ	WO	01/80844	A2		Inspire Pharmaceuticals	11-01-2001		
BR	WO	01/87288	A2		Inspire Pharmaceuticals	11-22-2001		
BS	WO	01/87913	A2		Inspire Pharmaceuticals	11-22-2001		
BT	WO	02/09702	A2		Inspire Phar., U. Compl. Madrid	02-07-2002		
BU	WO	02/16381	A2		Inspire Phar., U. No. Carolina	02-28-2002		
BV	WO	04/037167	A2		Molicem Medicines, Inc.	05-06-2004		

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
BW		BAUDOUIN, C., "The Pathology of Dry Eye," <i>Surv. Ophthalmol.</i> 45 Suppl. 2: S211-S220 (March 2001)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/531,660
				Filing Date	April 15, 2005
				First Named Inventor	Luis Molina
				Group Art Unit	1654
				Examiner Name	Marcela M. Cordero Garcia
Sheet	3	of	5	Attorney Docket Number	11299.105005 L1 3000 MMI/2

4005632\_1.DOC

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sub>6</sub>
	CA	BOSCHELLI, D.H., <i>et al.</i> , "Inhibition of E-selectin-, ICAM-1-, and VCAM-1-mediated cell adhesion by benzo[b]thiophene-, benzofuran-, indole-, and naphthalene-2-carboxamides: identification of PD 144795 as an antiinflammatory agent," <i>J. Med. Chem.</i> , 38(22):4597-4614 (October 27, 1995).	
	CB	BOUCHER, R., <i>et al.</i> , "Mechanisms and therapeutic actions of uridine triphosphates in the lungs," <i>Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology</i> , (L. Belardelli, <i>et al.</i> , Eds., Alumwer Academic Publishers, Boston, 1995), pp. 525-532.	
	CC	BOWIE, E.M., <i>et al.</i> , "Corticosteroids, central serous chorioretinopathy, and neurocysticercosis," <i>Arch. Ophthalmol.</i> , 122(2):281-283 (February 2004).	
	CD	BREWITT, H., <i>et al.</i> , "Dry Eye Disease: The Scale of the Problem." <i>Surv. Ophthalmol.</i> 45 Suppl. 2: S199-S202 March 2001.	
	CE	CHANG, Y.H., <i>et al.</i> , <i>Eur. J. Pharmacol.</i> , 69(2):155-164 (January 16, 1981). Effects of pharmacologic agents on the reversed passive Arthus reaction in the rat.	
	CF	CLOUTIER, M.M., <i>et al.</i> , "Duramycin enhances chloride channel activity in cystic fibrosis nasal epithelial cells." <i>Pediatric Pulmonology</i> , 2(Supplement):99 (Abstract 15) (1988).	
	CG	CLOUTIER, M.M., <i>et al.</i> , "Duramycin enhances chloride secretion in airway epithelium." <i>Am J Physiol. - Cell Physiol.</i> , Sep;259(3 Pt 1):C450-C454 (September 1990).	
	CH	DE NIJS, E., <i>et al.</i> , "The adverse effects of corticosteroids in central serous chorioretinopathy" <i>Bull. Soc. Belge Ophthalmol.</i> , 289:35-41 (2003).	
	CI	DIAMOND, M.S., <i>et al.</i> , "The dynamic regulation of integrin adhesiveness" <i>Current Biology</i> , 4(6):506-517 (June 1, 1994).	
	CJ	FORREST, J.B., <i>et al.</i> , "Activation of nasal cilia in immotile cilia syndrome , " <i>Am. Rev. Respir. Dis.</i> , 120(3):511-515 (September 1979).	
	CK	FOULKES, G.N., "The evolving treatment of dry eye," <i>Ophthalmol. Clin. North Am.</i> , 16(1):29-35 (March 2003).	
	CL	FRIEDLANDER, A.H., <i>et al.</i> , "Late-life depression: psychopathology, medical interventions, and dental implications," <i>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.</i> , 94(4):404-412 (October 2002).	
	CM		
	CN	GROSS, E., <i>et al.</i> , "Subtilin, VI: Die Struktur des Subtilins," <i>Z. Physiol. Chem.</i> , 354:810-812 (July 1973).	
	CO	HAYASHI, F., <i>et al.</i> , "The structure of PA48009: The revised structure of duramycin," <i>J. Antibiotics (Tokyo)</i> , LXIII(11):1421-1430 (November 1990).	
	CP	HÉCHARD, Y., <i>et al.</i> , "Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria," <i>Biochimie</i> , 84(5-6):545-557 (May-June 2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 A/PTO				<i>Complete if Known</i>	
				Application Number	10/531,660
				Filing Date	April 15, 2005
				First Named Inventor	Luis Molina
				Group Art Unit	1654
				Examiner Name	Marcela M. Cordero Garcia
Sheet	4	of	5	Attorney Docket Number	11299.105005 L1 3000 MMI/2

4005632\_1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. <sup>T 6</sup>			
	DA	KELLERMAN, D.J., "P2Y <sub>2</sub> Receptor agonists: a new class of medication targeted at improved mucociliary clearance," <i>Chest</i> , 121(5 Suppl.):201S-205S (May 2002).			
	DB	KELLNER, R., <i>et al.</i> , "Gallidermic: a new lanthionine-containing polypeptide antibiotic," <i>Eur. J. Biochem.</i> 177(1), 53-59 (October 15, 1988).			
	DC	KESSLER, H., <i>et al.</i> , "204. The structure of the polycyclic nonadecapeptide Ro 09-0198," <i>Helv. Chim. Acta</i> , 71:1924-1929 (1988).			
	DD	KETTENRING, J.K., <i>et al.</i> , "Sequence determination of actagardine, a novel lantibiotic, by homonuclear 2D NMR spectroscopy," <i>J. Antibiotics</i> , XLIII(9):1082-1088 (September 1990).			
	DE	KISHIMOTO, T.K., <i>et al.</i> , "Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites," <i>Adv. Pharmacol.</i> , 25:117-169 (1994).			
	DF	KNOWLES, M.R., <i>et al.</i> , "Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis," <i>N. Eng. J. Med.</i> , 325(8):533-538 (August 22, 1991).			
	DG	LANSLEY, A.B., <i>et al.</i> , "Control of the beat cycle of respiratory tract cilia by Ca <sup>2+</sup> and cAMP," <i>Am. J. Physiol.</i> , 263(2 Pt. 1):L232-L242 (August 1992).			
	DH	LETHEM, M.L., <i>et al.</i> , "Nucleotide regulation of goblet cells in human airway epithelial explants: normal exocytosis in cystic fibrosis," <i>Am. J. Respir. Cell. Mol. Biol.</i> , 9(3):315-322 (September 1993).			
	DI	McNULTY, M.J., <i>et al.</i> , "Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice," <i>Xenobiotica</i> , Feb;33(2):197-210 (February 2003).			
	DJ	MONNET, D., <i>et al.</i> , "Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases," <i>Ophthalmology</i> , 111(4):802-809 (April 2004).			
	DK	MUSZA, L.L., <i>et al.</i> , "Potent new cell adhesion inhibitors from the root of <i>trichilia rubra</i> ," <i>Tetrahedron</i> , 50(39):11369-11378 (1994).			
	DL	NAKAMURA, S., <i>et al.</i> , "Inhibitory effect of duramycin on partial reactions catalyzed by (Na <sup>+</sup> ,K <sup>+</sup> )-adenosinetriphosphatase from dog kidney," <i>Biochem.</i> , 23(2):385-389 (January 17, 1984).			
	DM	NUSSENBLATT, R.B., <i>et al.</i> , "Cyclosporine: immunology, pharmacology and therapeutic uses," <i>Survey of Ophthalmology</i> , 31(3):159-169 (November-December 1986).			
	DN	O'NEIL, M.J., Sr. Ed., <i>et al.</i> , <i>The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals</i> , 13 <sup>th</sup> Ed., O'Neil, M.J. Sr. Ed. (Merck & Co., Inc., Whitehouse Station, New Jersey, 2001), entry no. 2781 ("Cyclosporin A"), p. 480.			
	DO	PEDERSEN, M., "Ciliary activity and pollution," <i>Lung</i> , 168 Suppl.:368-376 (1990).			
	DP	PRIDHAM, T.G., <i>et al.</i> , "Antibiotics against plant disease. II. Effective agents produced by streptomyces cinnamomeus forma azacoluta F. Nov.," <i>Phytopathology</i> , 46:575-581 (October 1956)			
	DQ	ROBERTS, M., <i>et al.</i> , "Stimulation of sodium transport by duramycin in cultured human colonic epithelia," <i>J. Pharmacol. Exp. Ther.</i> , 259(3):1050-1058 (December 1991).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 A/PTO				<i>Complete if Known</i>	
				Application Number	10/531,660
				Filing Date	April 15, 2005
				First Named Inventor	Luis Molina
				Group Art Unit	1654
				Examiner Name	Marcela M. Cordero Garcia
Sheet	5	of	5	Attorney Docket Number	11299.105005 L1 3000 MMI/2

4005632\_1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	EA	SAHL, H.-G., "Influence of the staphylococcinlike peptide Pep 5 on membrane potential of bacterial cells and cytoplasmic membrane vesicles," <i>J. Bacteriol.</i> , 162(2):833-836 (May 1985).		
	EB	SANFILIPPO, P.J., <i>et al.</i> , "Novel thiazole based heterocycles as inhibitors of LFA-1/ICAM-1 mediated cell adhesion," <i>J. Med. Chem.</i> , 38(7):1057-1059 (March 31, 1995).		
	EC	SCHALENBURG, A., <i>et al.</i> , "Corticosteroid-induced central serous chorioretinopathy in patients with ocular inflammatory disorders," <i>Klinische Monatsblätter für Augenheilkunde</i> , 219(4):264-267 (April 2002).		
	ED	SCHNELL, N., <i>et al.</i> , "Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings," <i>Nature</i> , 333(6170):276-278 (May 19, 1988).		
	EE	SHOTWELL, O.L., <i>et al.</i> , "Antibiotics against plant disease. III. Duramycin, a new antibiotic from <i>Streptomyces cinnamomeus forma azacoluta</i> ," <i>J. Am. Chem. Soc.</i> 80:3912-3915 (August 5, 1958)		
	EF	SPRINGER, T.A., "Adhesion receptors of the immune system," <i>Nature</i> , 346(6283):425-434 (August 2, 1990).		
	EG	WAKAMIYA, T., <i>et al.</i> , "The structure of ancovenin, a new peptide inhibitor of Angiotensin I Converting Enzyme," <i>Tetrahedron Lett.</i> , 26(5):665-668 (1985).		
	EH	WANDEL, T., <i>et al.</i> , "Glaucoma treatment with once-daily levobunolol," <i>Amer. J. Ophthalmol.</i> , 101(3):298-304 (March 15, 1986).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

The U.S. Patent and Trademark Office official mailroom stamp affixed hereto acknowledges receipt of the items listed below.

Applicant: Luis Molina

Serial No.: 10/531,660

Filed: September 22, 2003

For: Methods of Treating Dry Eye Disease with Lantibiotics

Papers Submitted:

1. Information Disclosure Statement (1 page)
2. Form PTO/SB/08A (5 pages)
3. Copy of References (61 references)
4. Certificate of Mailing *57*
5. Postcard

Attorney Stephanie D. Adams, Ph.D.

Date Mailed February 17, 2006

Docket 11299.105005 L1 3000 MMI/2

4005641\_1.DOC